FDA actions among top read dermatology articles of the week

The top read articles in Healio.com/Dermatology during the past week included dermatologists’ perspectives on the recent FDA approval of Kybella for treating submental fat and the agency’s tentative approval for generic plaque psoriasis treatment.

Study results that captured readers’ interest included Humira providing faster clinical disease response vs. methotrexate for treatment of psoriasis:

Perspectives: FDA approves ATX-101 for treatment of submental fat

The FDA announced it has approved Kybella, also known as ATX-101, for the treatment of moderate-to-severe submental fat in adults.

Alastair Carruthers

Dermatologist who also served as researchers on the product, including Alastair Carruthers, FRCPC, offer perspectives. Read more

FDA grants Glenmark tentative abbreviated NDA approval for generic plaque psoriasis treatment

Glenmark Pharmaceuticals USA announced it has received tentative FDA approval for calcipotriene cream, 0.005% — the company’s generic equivalent of topical Donovex Cream, 0.005%, which is indicated for the treatment of plaque psoriasis. Read more

Study: Humira provides faster clinical disease response vs. methotrexate for treatment of psoriasis

Humira provided faster and more complete clinical disease responses compared with methotrexate as treatment for plaque psoriasis, according to recently published study results.

Researchers conducted an assessor-blind clinical trial of 30 patients between the ages of 18 years and 85 years with chronic plaque-type psoriasis who were treated at the outpatient dermatology center of Tufts Medical Center, Boston. Patients were randomly assigned to receive a 16-week course of subcutaneous Humira(adalimumab, AbbVie), or oral methotrexate. Read more

Vismodegib fails to meet primary efficacy endpoints for treatment of patients with BCC

Erivedge (vismodegib, Genentech) did not meet primary efficacy endpoints of predefined histologic clearance rates in patients with basal cell carcinoma who received the treatment prior to excision; however, drug-related adverse events were reversible upon treatment completion, according to recently published study results. Read more

Patients with atopic dermatitis may have slightly increased lymphoma risk

Patients with atopic dermatitis had a slightly increased risk of lymphoma, with the severity of atopic dermatitis a potentially significant risk factor, according to recently published study results.

Researchers conducted a systematic literature review to identify articles published between 1980 and Feb. 28, 2014, that investigated lymphoma risk in patients with atopic dermatitis. Read more